Association between metabolic syndrome and menopausal symptoms in perimenopause

Authors

  • Aneta Sima University Clinic for Gynecology and Obstetrics; Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Ana Daneva-Markova University Clinic for Gynecology and Obstetrics; Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Slagana Simeonova-Krstevska University Clinic for Gynecology and Obstetrics; Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Vesna Livrinova University Clinic for Gynecology and Obstetrics; Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Drage Dabeski University Clinic for Gynecology and Obstetrics; Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia

DOI:

https://doi.org/10.3889/aph.2026.6656

Keywords:

perimenopause, metabolic syndrome, menopausal symptoms

Abstract

The perimenopausal transition is characterized by hormonal fluctuations that trigger physical and psychological symptoms while simultaneously increasing the risk of metabolic syndrome. Understanding the link between these physiological shifts is crucial for preventing long-term cardiovascular and endocrine complications. Aim of the study was to determine the prevalence of metabolic syndrome (MS) in perimenopausal women and evaluate the association between the severity of menopausal symptoms and MS components. Materials and methods: This prospective cohort study was conducted over a one- year period (2021-2022) at the University Clinic for Gynaecology and Obstetrics. The study included 100 perimenopausal patients (aged 45–50) with abnormal uterine bleeding, categorized by BMI: group I (BMI > 30), group II (BMI up to 30), and a control group (n=40) of asymptomatic women. Data were collected via the Menopause Quick 6 assessment tool and laboratory biochemical analyses (lipid status, glycemia, blood pressure, and anthropometric measurements). Results: The prevalence of metabolic syndrome was significantly higher in patients of group I (80.3%) and group II (41.2%) compared to the control group (17.5%). While MS prevalence was similar between premenopausal (52.9%) and perimenopausal (52.8%) patients, specific symptoms showed strong statistical correlations. In group I (p < 0.05), metabolic syndrome and hot flashes, insomnia, and bone pain were significantly associated. In group II, insomnia remained significantly associated with MS (p = 0.0326). Hot flashes were the most prevalent symptom in group I (93.9%), while insomnia predominated in group II (73.5%). Conclusion: The study demonstrates a significant link between the intensity of menopausal symptoms - particularly vasomotor symptoms and sleep disturbances - and the prevalence of metabolic syndrome. These findings suggest that severe menopausal symptoms may serve as early clinical indicators of metabolic risk. An integrated clinical approach addressing both hormonal shifts and metabolic health is essential for reducing long-term cardiovascular and diabetic risks in perimenopausal women.

Downloads

Download data is not yet available.

References

1. Carr M C. The emergence of the metabolic syndrome with menopause. The Journal of Clinical Endocrinology & Metabolism 2003; 88(6): 2404-2411. https://doi.org/10.1210/jc.2003-030242

2. Jaspers L, Daan N M, van Dijk G M, et al. Health in middle-aged and elderly women: A conceptual framework for healthy menopause. Maturitas 2015; 81(1): 93-98. https://doi.org/10.1016/j.maturitas.2015.02.001

3. Muka T, Oliver-Williams C, Kunutsor S, et al. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: A systematic review and meta-analysis. PLOS ONE 2016; 11(6): e0157417. https://doi.org/10.1371/journal.pone.0157417

4. Rosano G M, Vitale C, Fini M. Metabolic syndrome in women: Menopause-related changes and effects of hormone replacement therapy. Drugs & Aging 2006 23(9): 623-630. https://doi.org/10.2165/00002512-200623090-00001

5. Zhu D, Chung H F, Pandeya N, et al. Body mass index and age at natural menopause: An international pooled analysis of 11 prospective studies. European Journal of Epidemiology 2019; 34(8): 785-797. https://doi.org/10.1007/s10654- 019-00535-w

6. Janssen I, Powell L H, Kazlauskaite R, et al. Menopausal transition and increases in fat mass: A 9-year follow-up. Obesity 2008; 16(5): 1116-1121. https://doi.org/10.1038/oby.2008.91

7. Kim C, Chang Y, Cho Y K, et al. Menopausal symptoms and metabolic syndrome in Korean middle-aged women. Maturitas 2017; 106: 70-77. https://doi.org/10.1016/j.maturitas.2017.08.012

8. Polotsky H N, Polotsky A J. Metabolic implications of menopause. Seminars in Reproductive Medicine 2010; 28(5): 426-434. https://doi.org/10.1055/s-0030- 1262902

9. Wildman R P, Tepper P G, Crawford S, et al. Progression of metabolic syndrome and its components after menopause: Results from the Study of Women's Health Across the Nation (SWAN). Menopause 2012; 19(6): 610-616. https://doi.org/10.1097/gme.0b013e318238f6aa

10. DeFina L F, Radford N B, Leonard D, et al. Association of vasomotor symptoms with coronary artery calcium in the Dallas Heart Study. Menopause 2016; 23(5): 499-504. https://doi.org/10.1097/GME.0000000000000595

11. Freeman E W, Sherif K. Prevalence of hot flashes and night sweats around the world: A systematic review. Climacteric 2007; 10(3): 197-214. https://doi.org/10.1080/13697130701268075

12. Harlow S D, Gass M, Hall J E, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. Fertility and Sterility 2012; 97(4): 843-851. https://doi.org/10.1016/j.fertnstert.2012.01.128

13. Avis N E, Crawford S L, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine 2015; 175(4): 531-539. https://doi.org/10.1001/jamainternmed.2014.8063

14. Thurston R C, Joffe H. Vasomotor symptoms and menopause: Findings from the Study of Women's Health Across the Nation. Obstetrics and Gynecology Clinics of North America 2011; 38(3): 489-501. https://doi.org/10.1016/j.ogc.2011.05.006

15. Brown W J, Mishra G, Dobson A, et al. Changes in physical symptoms during the menopause transition. International Journal of Behavioral Medicine 2000; 7(1): 53-67. https://doi.org/10.1207/S15327558IJBM0701_5

16. Tafeit E, Sudi K, Poglitsch H, et al. Menopause and body mass index: A study in 498 middle-aged women. Acta Medica Austriaca 2006; 33(3): 90-93. https://doi.org/10.1046/j.1563-2571.2006.00305.x

17. Hallajzadeh J, Khoramdad M, Izadi N, Karamzad N, Almasi-Hashiani A, Ayubi E, et al. Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta-analysis on observational studies. Menopause. 2018; 25(10):1155-1164. doi: 10.1097/GME.0000000000001136. PMID: 29787477.

Published

2026-07-25

How to Cite

1.
Sima A, Daneva-Markova A, Simeonova-Krstevska S, Livrinova V, Dabeski D. Association between metabolic syndrome and menopausal symptoms in perimenopause. Arch Pub Health [Internet]. 2026 Jul. 25 [cited 2026 Nov. 21];18(1):26-33. Available from: https://journals.mk/index.php/aph/article/view/6656

Issue

Section

Clinical Science

Most read articles by the same author(s)